We are live on ! Find out more
PPH icon

VanEck Pharmaceutical ETF
PPH

102 hedge funds and large institutions have $392M invested in VanEck Pharmaceutical ETF in 2023 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 35 increasing their positions, 29 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

207% more call options, than puts

Call options by funds: $780K | Put options by funds: $254K

21% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 29

11.21% more ownership

Funds ownership: 96.14% → 107.35% (+11%)

10% more capital invested

Capital invested by funds: $356M → $392M (+$36.1M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

4% less funds holding

Funds holding: 106 → 102 (-4)

22% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 18

Holders
102
Holders Change
-4
Holders Change %
-3.77%
% of All Funds
1.6%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
14
Increased
35
Reduced
29
Closed
18
Calls
$780K
Puts
$254K
Net Calls
+$526K
Net Calls Change
-$3.81M

Top Buyers

Rank Fund Capital Flow
1
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
+$23.5M
2
Bank of America
Bank of America
North Carolina
+$18.5M
3
PCIA
Prime Capital Investment Advisors
Kansas
+$11.5M
4
MIM
Miller Investment Management
Pennsylvania
+$11.1M
5
PF
Phoenix Financial
Israel
+$8.81M

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$37.9M
2
HF
HRT Financial
New York
-$5.21M
3
Morgan Stanley
Morgan Stanley
New York
-$2.78M
4
SIM
Seaview Investment Managers
Florida
-$2.04M
5
AC
ASB Consultores
Florida
-$1.88M
Name Holding Trade Value Shares
Change 		Change in
Stake
DF
76
DecisionPoint Financial
Arizona
$78.8K – – –
William Blair & Company
77
William Blair & Company
Illinois
$69.5K – – –
Northwestern Mutual Wealth Management
78
Northwestern Mutual Wealth Management
Wisconsin
$69.4K +$35.4K +452 +105%
BCV
79
Banque Cantonale Vaudoise
Switzerland
$56K -$3.52K -45 -6%
CIAS
80
Capital Investment Advisory Services
North Carolina
$37.4K -$11.7K -150 -24%
EDRH
81
Edmond de Rothschild Holding
Switzerland
$33.2K – – –
FDCDDQ
82
Federation des caisses Desjardins du Quebec
Quebec, Canada
$31.5K – – –
RCM
83
Raleigh Capital Management
North Carolina
$20.3K +$157 +2 +0.8%
HPC
84
HM Payson & Co
Maine
$19.5K – – –
Fidelity Investments
85
Fidelity Investments
Massachusetts
$17.1K – – –
IA
86
IFP Advisors
Florida
$17K -$2.82K -36 -14%
AF
87
Advisornet Financial
Minnesota
$15.8K – – –
IGWM
88
ICA Group Wealth Management
Colorado
$12.5K +$12.4K +159 New
HCM
89
Highlander Capital Management
New Jersey
$11K – – –
YDMI
90
Y.D. More Investments
Israel
$9.45K – – –
BBPWM
91
Blue Bell Private Wealth Management
Pennsylvania
$6.14K – – –
GRP
92
Global Retirement Partners
California
$5.91K – – –
AF
93
Allworth Financial
California
$5.83K +$5.79K +74 New
VanEck Associates
94
VanEck Associates
New York
$5K – – –
MIM
95
Macroview Investment Management
Maryland
$4.96K – – –
AIM
96
Anchor Investment Management
South Carolina
$4.57K – – –
CAS
97
Coppell Advisory Solutions
Texas
$4.1K +$4.07K +52 New
VF
98
VitalStone Financial
Texas
$4K +$4.3K +55 New
SWA
99
SOA Wealth Advisors
New York
$2.65K +$78 +1 +3%
FWM
100
Focused Wealth Management
New York
$1.1K – – –
1 2 3
4
5

PPH Hedge Fund Activity: Q2 2023 in Review

102 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q2 2023, worth a combined $392M — up 10% from $356M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of PPH and 14 opened new positions — a net loss of 4 holders — while 29 trimmed existing stakes and 35 added.

The largest buyer was BNP Paribas Financial Markets, adding an estimated $23.5M. The largest seller was Goldman Sachs, cutting an estimated $37.9M.

  • 102 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q2 2023, down from 106 in Q1 2023.
  • Funds reported $392M of VanEck Pharmaceutical ETF stock for Q2 2023, up 10% quarter-over-quarter.
  • 14 funds opened new VanEck Pharmaceutical ETF positions in Q2 2023 and 18 closed out, a net change of -4 holders.
  • The largest VanEck Pharmaceutical ETF buyer in Q2 2023 was BNP Paribas Financial Markets, an estimated $23.5M added.
  • The largest VanEck Pharmaceutical ETF seller in Q2 2023 was Goldman Sachs, an estimated $37.9M sold.

Based on aggregated 13F filings for Q2 2023.